Poly-lactide/Poly-lactide-co-glycolide-Based Delivery System for Bioactive Compounds Against Microbes

  • Robin Kumar
  • Divya Jha
  • Amulya K. PandaEmail author
Part of the Environmental Chemistry for a Sustainable World book series (ECSW, volume 26)


Infectious diseases caused by pathogenic microorganisms are one of the leading causes of mortality worldwide. For many of these diseases, prophylactic and therapeutic treatments are available in the form of vaccines and drugs. Novel discoveries in the pathophysiology and immunology of these diseases have led to the identification of contributing factors to the progress of these diseases. Our immune system puts forth a strong defense against these infections, but the microbes develop strategies to evade the immune system and survive inside the host. There is an ongoing hunt to look for potent therapeutic agents against these harmful bugs. These therapeutic drugs also need to be delivered effectively for long-lasting protection. This has led to the enhanced emphasis on the type of a suitable delivery system that can carry these agents inside the human body in its bioactive form. Hence, to achieve newer ways to deal with infection, we need better delivery systems as powerful tools for infection control and treatment.

Biodegradable and biocompatible polymeric particles such as poly(lactic acid) and poly(lactic-co-glycolic acid) have emerged as one of the efficient delivery systems for many life-saving drugs. These polymers offer several advantages such as targeted delivery, sustained release, and maintenance of bioactivity; it also leads to dose sparing by reducing the exposure of bioactive molecules in the circulation. The polymeric particles are being extensively studied in several applications as delivery systems due to their ability to exhibit a broad range of desirable properties. The present review focuses on the polymer-based particulate delivery system as a plausible solution to circumvent the shortcomings of conventional therapeutic and prophylactic systems, and it discusses some of the methods for their preparation as well as mechanisms of action against infection. Here we also review the cellular interaction of nanoparticles because this interaction influences the effectiveness of the particles. The present review aims at different preparation methods of poly-lactide/poly-lactide-co-glycolide-based particles, their properties as carriers of bioactive molecules, and applications of polymeric particle-based bioactive delivery systems against microbes with an emphasis on recent findings. This review sheds light on the latest applications of particle-based delivery systems attempting to provide an updated study about the field.


Infectious diseases Microbes Therapeutic targets Biodegradable polymer Poly(lactic acid) Poly(lactic-co-glycolic acid) Nanoparticle Microparticle Scaffold Bioactive delivery system 



The authors are grateful to the National Institute of Immunology for financial support.

Competing Interests

The authors declare that they have no competing interests.


  1. Admane P, Gupta J, Ancy I, Kumar R, Panda AK (2017) Design and evaluation of antibiotic releasing self-assembled scaffolds at room temperature using biodegradable polymer particles. Int J Pharm 520(1):284–296. CrossRefGoogle Scholar
  2. Agallou M, Margaroni M, Athanasiou E, Toubanaki DK, Kontonikola K, Karidi K, Kammona O, Kiparissides C, Karagouni E (2017) Identification of BALB/c immune markers correlated with a partial protection to Leishmania infantum after vaccination with a rationally designed multi-epitope cysteine protease a peptide-based nanovaccine. PLoS Negl Trop Dis 11(1):e0005311. CrossRefGoogle Scholar
  3. Aldrian G, Vaissière A, Konate K, Seisel Q, Vivès E, Fernandez F, Viguier V, Genevois C, Couillaud F, Démèné H (2017) PEGylation rate influences peptide-based nanoparticles mediated siRNA delivery in vitro and in vivo. J Control Release 256:79–91. CrossRefGoogle Scholar
  4. Allahyari M, Mohit E (2016) Peptide/protein vaccine delivery system based on PLGA particles. Hum Vaccin Immunother 12(3):806–828. CrossRefGoogle Scholar
  5. Allahyari M, Mohabati R, Amiri S, Rastaghi ARE, Babaie J, Mahdavi M, Vatanara A, Golkar M (2016) Synergistic effect of rSAG1 and rGRA2 antigens formulated in PLGA microspheres in eliciting immune protection against Toxoplasama gondii. Exp Parasitol 170:236–246. CrossRefGoogle Scholar
  6. Anderson JM, Shive MS (2012) Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 64:72–82. CrossRefGoogle Scholar
  7. Athanasiou E, Agallou M, Tastsoglou S, Kammona O, Hatzigeorgiou A, Kiparissides C, Karagouni E (2017) A poly (lactic-co-glycolic) acid nanovaccine based on chimeric peptides from different Leishmania infantum proteins induces dendritic cells maturation and promotes peptide-specific IFNγ-producing CD8+ T cells essential for the protection against experimental visceral Leishmaniasis. Front Immunol 8:684. CrossRefGoogle Scholar
  8. Basu A, Kunduru KR, Doppalapudi S, Domb AJ, Khan W (2016) Poly (lactic acid) based hydrogels. Adv Drug Deliv Rev 107:192–205. CrossRefGoogle Scholar
  9. Bhatt PC, Verma A, Al-Abbasi FA, Anwar F, Kumar V, Panda BP (2017) Development of surface-engineered PLGA nanoparticulate-delivery system of Tet1-conjugated nattokinase enzyme for inhibition of Aβ40 plaques in Alzheimer’s disease. Int J Nanomedicine 12:8749–8768.
  10. Brady JM, Cutright DE, Miller RA, Battistone GC, Hunsuck EE (1973) Resorption rate, route of elimination, and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat. J Biomed Mater Res A 7(2):155–166. CrossRefGoogle Scholar
  11. Bruno C, Agnolon V, Berti F, Bufali S, O’Hagan DT, Baudner BC (2016) The preparation and characterization of PLG nanoparticles with an entrapped synthetic TLR7 agonist and their preclinical evaluation as adjuvant for an adsorbed DTaP vaccine. Eur J Pharm Biopharm 105:1–8. CrossRefGoogle Scholar
  12. Cai H, Liang Z, Huang W, Wen L, Chen G (2017) Engineering PLGA nano-based systems through understanding the influence of nanoparticle properties and cell-penetrating peptides for cochlear drug delivery. Int J Pharm 532(1):55–65. CrossRefGoogle Scholar
  13. Carreño JM, Perez-Shibayama C, Gil-Cruz C, Printz A, Pastelin R, Isibasi A, Chariatte D, Tanoue Y, Lopez-Macias C, Gander B (2016) PLGA-microencapsulation protects Salmonella typhi outer membrane proteins from acidic degradation and increases their mucosal immunogenicity. Vaccine 34(35):4263–4269. CrossRefGoogle Scholar
  14. Chong CS, Cao M, Wong WW, Fischer KP, Addison WR, Kwon GS, Tyrrell DL, Samuel J (2005) Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Control Release 102(1):85–99. CrossRefGoogle Scholar
  15. Coelho JF, Ferreira PC, Alves P, Cordeiro R, Fonseca AC, Góis JR, Gil MH (2010) Drug delivery systems: advanced technologies potentially applicable in personalized treatments. EPMA J 1(1):164–209. CrossRefGoogle Scholar
  16. Cruz J, Flórez J, Torres R, Urquiza M, Gutiérrez J, Guzmán F, Ortiz C (2017) Antimicrobial activity of a new synthetic peptide loaded in polylactic acid or poly (lactic-co-glycolic) acid nanoparticles against Pseudomonas aeruginosa, Escherichia coli O157: H7 and methicillin resistant Staphylococcus aureus (MRSA). Nanotechnology 28(13):135102. CrossRefGoogle Scholar
  17. Dalzon B, Lebas C, Jimenez G, Gutjahr A, Terrat C, Exposito J-Y, Verrier B, Lethias C (2016) Poly (lactic acid) nanoparticles targeting α5β1 integrin as vaccine delivery vehicle, a prospective study. PLoS One 11(12):e0167663. CrossRefGoogle Scholar
  18. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V (2012) PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161(2):505–522. CrossRefGoogle Scholar
  19. Dhakal S, Hiremath J, Bondra K, Lakshmanappa YS, Shyu D-L, Ouyang K, Kang K-i, Binjawadagi B, Goodman J, Tabynov K (2017) Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs. J Control Release 247:194–205. CrossRefGoogle Scholar
  20. Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F (2011) Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine 6:877. CrossRefGoogle Scholar
  21. Du X, Wang J-L, Iqbal S, Li H, Cao Z, Wang Y-C, Du J, Wang J (2018) The effect of surface charge on oral absorption of polymeric nanoparticles. Biomater Sci 6:642. CrossRefGoogle Scholar
  22. Ekanem EE, Zhang Z, Vladisavljevic GT (2017a) Facile production of biodegradable bipolymer patchy and patchy Janus particles with controlled morphology by microfluidic routes. Langmuir 33(34):8476–8482. CrossRefGoogle Scholar
  23. Ekanem EE, Zhang Z, Vladisavljević GT (2017b) Facile microfluidic production of composite polymer core-shell microcapsules and crescent-shaped microparticles. J Colloid Interface Sci 498:387–394. CrossRefGoogle Scholar
  24. El-Hammadi MM, Delgado ÁV, Melguizo C, Prados JC, Arias JL (2017) Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil. Int J Pharm 516(1):61–70. CrossRefGoogle Scholar
  25. Fröhlich E (2012) The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine 7:5577. CrossRefGoogle Scholar
  26. Gagliardi M, Bertero A, Bifone A (2017) Molecularly imprinted biodegradable nanoparticles. Sci Rep 7.
  27. Genta I, Colonna C, Conti B, Caliceti P, Salmaso S, Speziale P, Pietrocola G, Chiesa E, Modena T, Dorati R (2016) CNA-loaded PLGA nanoparticles improve humoral response against S. aureus-mediated infections in a mouse model: subcutaneous vs. nasal administration strategy. J Microencapsul 33(8):750–762. CrossRefGoogle Scholar
  28. Gourdon B, Chemin C, Moreau A, Arnauld T, Baumy P, Cisternino S, Péan J-M, Declèves X (2017) Functionalized PLA-PEG nanoparticles targeting intestinal transporter PepT1 for oral delivery of acyclovir. Int J Pharm 529(1–2):357–370. CrossRefGoogle Scholar
  29. Gregory AE, Titball R, Williamson D (2013) Vaccine delivery using nanoparticles. Front Cell Infect Microbiol 3:13. CrossRefGoogle Scholar
  30. Gutierro I, Hernandez R, Igartua M, Gascon A, Pedraz J (2002) Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 21(1):67–77. CrossRefGoogle Scholar
  31. Gutjahr A, Phelip C, Coolen A-L, Monge C, Boisgard A-S, Paul S, Verrier B (2016) Biodegradable polymeric nanoparticles-based vaccine adjuvants for lymph nodes targeting. Vaccine 4(4):34. CrossRefGoogle Scholar
  32. Hillaireau H, Couvreur P (2009) Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66(17):2873–2896. CrossRefGoogle Scholar
  33. Hiremath J, Kang K-i, Xia M, Elaish M, Binjawadagi B, Ouyang K, Dhakal S, Arcos J, Torrelles JB, Jiang X (2016) Entrapment of H1N1 influenza virus derived conserved peptides in PLGA nanoparticles enhances T cell response and vaccine efficacy in pigs. PLoS One 11(4):e0151922. CrossRefGoogle Scholar
  34. Huang N, Lu S, Liu X-G, Zhu J, Wang Y-J, Liu R-T (2017) PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Aβ generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer’s disease mice. Oncotarget 8(46):81001. CrossRefGoogle Scholar
  35. Hussain M, Xie J, Hou Z, Shezad K, Xu J, Wang K, Gao Y, Shen L, Zhu J (2017) Regulation of drug release by tuning surface textures of biodegradable polymer microparticles. ACS Appl Mater Interfaces 9(24):14391–14400. CrossRefGoogle Scholar
  36. James R, Manoukian OS, Kumbar SG (2016) Poly (lactic acid) for delivery of bioactive macromolecules. Adv Drug Deliv Rev 107:277–288. CrossRefGoogle Scholar
  37. Jannuzzi GP, de Araújo Souza N, Françoso KS, Pereira RH, Santos RP, Kaihami GH, de Almeida JRF, Batista WL, Amaral AC, Maranhão AQ (2017) Therapeutic treatment with scFv–PLGA nanoparticles decreases pulmonary fungal load in a murine model of paracoccidioidomycosis. Microbes Infect 20:48. CrossRefGoogle Scholar
  38. Johansen P, Men Y, Merkle HP, Gander B (2000) Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm 50(1):129–146. CrossRefGoogle Scholar
  39. Kasturi SP, Kozlowski PA, Nakaya HI, Burger MC, Russo P, Pham M, Kovalenkov Y, Silveira EL, Havenar-Daughton C, Burton SL (2017) Adjuvanting a simian immunodeficiency virus vaccine with toll-like receptor ligands encapsulated in nanoparticles induces persistent antibody responses and enhanced protection in TRIM5α restrictive macaques. J Virol 91(4):e01844–e01816. CrossRefGoogle Scholar
  40. Koutsiouki K, Angelopoulou A, Ioannou E, Voulgari E, Sergides A, Magoulas GE, Bakandritsos A, Avgoustakis K (2017) TAT peptide-conjugated magnetic PLA-PEG nanocapsules for the targeted delivery of paclitaxel: in vitro and cell studies. AAPS PharmSciTech 18(3):769–781. CrossRefGoogle Scholar
  41. Li P, Asokanathan C, Liu F, Khaing KK, Kmiec D, Wei X, Song B, Xing D, Kong D (2016) PLGA nano/micro particles encapsulated with pertussis toxoid (PTd) enhances Th1/Th17 immune response in a murine model. Int J Pharm 513(1):183–190. CrossRefGoogle Scholar
  42. Liu L, Cao F, Liu X, Wang H, Zhang C, Sun H, Wang C, Leng X, Song C, Kong D (2016a) Hyaluronic acid-modified cationic lipid–PLGA hybrid nanoparticles as a nanovaccine induce robust humoral and cellular immune responses. ACS Appl Mater Interfaces 8(19):11969–11979. CrossRefGoogle Scholar
  43. Liu L, Ma P, Wang H, Zhang C, Sun H, Wang C, Song C, Leng X, Kong D, Ma G (2016b) Immune responses to vaccines delivered by encapsulation into and/or adsorption onto cationic lipid-PLGA hybrid nanoparticles. J Control Release 225:230–239. CrossRefGoogle Scholar
  44. Marasini N, Khalil ZG, Giddam AK, Ghaffar KA, Hussein WM, Capon RJ, Batzloff MR, Good MF, Skwarczynski M, Toth I (2016) Lipid core peptide/poly (lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against group A streptococcus. Int J Pharm 513(1):410–420. CrossRefGoogle Scholar
  45. Margaroni M, Agallou M, Kontonikola K, Karidi K, Kammona O, Kiparissides C, Gaitanaki C, Karagouni E (2016) PLGA nanoparticles modified with a TNFα mimicking peptide, soluble Leishmania antigens and MPLA induce T cell priming in vitro via dendritic cell functional differentiation. Eur J Pharm Biopharm 105:18–31. CrossRefGoogle Scholar
  46. Meng Q, Wang A, Hua H, Jiang Y, Wang Y, Mu H, Wu Z, Sun K (2018) Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer’s disease. Int J Nanomedicine 13:705. CrossRefGoogle Scholar
  47. Metz SW, Tian S, Hoekstra G, Yi X, Stone M, Horvath K, Miley MJ, DeSimone J, Luft CJ, de Silva AM (2016) Precisely molded nanoparticle displaying DENV-E proteins induces robust serotype-specific neutralizing antibody responses. PLoS Negl Trop Dis 10(10):e0005071. CrossRefGoogle Scholar
  48. Mitragotri S, Burke PA, Langer R (2014) Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov 13(9):655. CrossRefGoogle Scholar
  49. Murariu M, Dubois P (2016) PLA composites: from production to properties. Adv Drug Deliv Rev 107:17–46. CrossRefGoogle Scholar
  50. Nabi H, Rashid I, Ahmad N, Durrani A, Akbar H, Islam S, Bajwa AA, Shehzad W, Ashraf K, Imran N (2017) Induction of specific humoral immune response in mice immunized with ROP18 nanospheres from Toxoplasma gondii. Parasitol Res 116(1):359–370. CrossRefGoogle Scholar
  51. Oyewumi MO, Kumar A, Cui Z (2010) Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 9(9):1095–1107. CrossRefGoogle Scholar
  52. Pagels RF, Prud’homme RK (2015) Polymeric nanoparticles and microparticles for the delivery of peptides, biologics, and soluble therapeutics. J Control Release 219:519–535. CrossRefGoogle Scholar
  53. Pandey SK, Patel DK, Maurya AK, Thakur R, Mishra DP, Vinayak M, Haldar C, Maiti P (2016) Controlled release of drug and better bioavailability using poly (lactic acid-co-glycolic acid) nanoparticles. Int J Biol Macromol 89:99–110. CrossRefGoogle Scholar
  54. Panyam J, Labhasetwar V (2003) Dynamics of endocytosis and exocytosis of poly (D, L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res 20(2):212–220. CrossRefGoogle Scholar
  55. Panyam J, Zhou W-Z, Prabha S, Sahoo SK, Labhasetwar V (2002) Rapid endo-lysosomal escape of poly (DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 16(10):1217–1226. CrossRefGoogle Scholar
  56. Parumasivam T, Leung SSY, Quan DH, Triccas JA, Britton WJ, Chan H-K (2016) Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: preparation and in vitro aerosol characterization. Eur J Pharm Sci 88(Supplement C):1–11. CrossRefGoogle Scholar
  57. Pei Y, Mohamed MF, Seleem MN, Yeo Y (2017) Particle engineering for intracellular delivery of vancomycin to methicillin-resistant Staphylococcus aureus (MRSA)-infected macrophages. J Control Release 267:133. CrossRefGoogle Scholar
  58. Peres C, Matos AI, Conniot J, Sainz V, Zupančič E, Silva JM, Graça L, Gaspar RS, Préat V, Florindo HF (2017) Poly (lactic acid)-based particulate systems are promising tools for immune modulation. Acta Biomater 48:41–57. CrossRefGoogle Scholar
  59. Peyre M, Audran R, Estevez F, Corradin G, Gander B, Sesardic D, Johansen P (2004) Childhood and malaria vaccines combined in biodegradable microspheres produce immunity with synergistic interactions. J Control Release 99(3):345–355. CrossRefGoogle Scholar
  60. Qu S, Zhao L, Zhu J, Wang C, Dai C, Guo H, Hao Z (2017) Preparation and testing of cefquinome-loaded poly lactic-co-glycolic acid microspheres for lung targeting. Drug Deliv 24(1):745–751. CrossRefGoogle Scholar
  61. Raudszus B, Mulac D, Langer K (2018) A new preparation strategy for surface modified PLA nanoparticles to enhance uptake by endothelial cells. Int J Pharm 536(1):211–221. CrossRefGoogle Scholar
  62. Roointan A, Kianpour S, Memari F, Gandomani M, Gheibi Hayat SM, Mohammadi-Samani S (2018) Poly (lactic-co-glycolic acid): the most ardent and flexible candidate in biomedicine! Int J Polym Mater Polym Biomater 67:1–22. CrossRefGoogle Scholar
  63. Roopngam P, Liu K, Mei L, Zheng Y, Zhu X, Tsai H-I, Huang L (2016) Hepatitis C virus E2 protein encapsulation into poly d, l-lactic-co-glycolide microspheres could induce mice cytotoxic T-cell response. Int J Nanomedicine 11:5361. CrossRefGoogle Scholar
  64. Ruge CA, Hillaireau H, Grabowski N, Beck-Broichsitter M, Cañadas O, Tsapis N, Casals C, Nicolas J, Fattal E (2016) Pulmonary surfactant protein A-mediated enrichment of surface-decorated polymeric nanoparticles in alveolar macrophages. Mol Pharm 13(12):4168–4178. CrossRefGoogle Scholar
  65. Sabaeifard P, Abdi-Ali A, Gamazo C, Irache JM, Soudi MR (2017) Improved effect of amikacin-loaded poly (D, L-lactide-co-glycolide) nanoparticles against planktonic and biofilm cells of Pseudomonas aeruginosa. J Med Microbiol 66(2):137–148. CrossRefGoogle Scholar
  66. Saffer EM, Tew GN, Bhatia SR (2011) Poly (lactic acid)-poly (ethylene oxide) block copolymers: new directions in self-assembly and biomedical applications. Curr Med Chem 18(36):5676–5686. CrossRefGoogle Scholar
  67. Sahin A, Esendagli G, Yerlikaya F, Caban-Toktas S, Yoyen-Ermis D, Horzum U, Aktas Y, Khan M, Couvreur P, Capan Y (2017) A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles’ characteristics and efficacy of intracellular delivery. Artif Cells Nanomed Biotechnol 45:1–11. CrossRefGoogle Scholar
  68. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L (2016) Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases. J Control Release 235:34–47. CrossRefGoogle Scholar
  69. Seok H, Noh JY, Lee DY, Kim SJ, Song CS, Kim YC (2017) Effective humoral immune response from a H1N1 DNA vaccine delivered to the skin by microneedles coated with PLGA-based cationic nanoparticles. J Control Release 265:66. CrossRefGoogle Scholar
  70. Shah RR, O’Hagan DT, Amiji MM, Brito LA (2014) The impact of size on particulate vaccine adjuvants. Nanomedicine 9(17):2671–2681. CrossRefGoogle Scholar
  71. Silva A, Soema P, Slütter B, Ossendorp F, Jiskoot W (2016) PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity. Hum Vaccin Immunother 12(4):1056–1069. CrossRefGoogle Scholar
  72. Song C, Noh Y-W, Lim YT (2016) Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response. Int J Nanomedicine 11:3753. CrossRefGoogle Scholar
  73. Steinbach JM, Seo Y-E, Saltzman WM (2016) Cell penetrating peptide-modified poly (lactic-co-glycolic acid) nanoparticles with enhanced cell internalization. Acta Biomater 30:49–61. CrossRefGoogle Scholar
  74. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99:28–51. CrossRefGoogle Scholar
  75. Sun Z, Yan X, Liu Y, Huang L, Kong C, Qu X, Wang M, Gao R, Qin H (2017) Application of dual targeting drug delivery system for the improvement of anti-glioma efficacy of doxorubicin. Oncotarget 8(35):58823. CrossRefGoogle Scholar
  76. Tan Z, Liu W, Liu H, Li C, Zhang Y, Meng X, Tang T, Xi T, Xing Y (2017) Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection. Eur J Pharm Biopharm 111:33–43. CrossRefGoogle Scholar
  77. Thomas N, Thorn C, Richter K, Thierry B, Prestidge C (2016) Efficacy of poly-lactic-co-glycolic acid micro-and nanoparticles of ciprofloxacin against bacterial biofilms. J Pharm Sci 105(10):3115–3122. CrossRefGoogle Scholar
  78. Tran TH, Tran TTP, Nguyen HT, Dai Phung C, Jeong J-H, Stenzel MH, Jin SG, Yong CS, Truong DH, Kim JO (2018) Nanoparticles for dendritic cell-based immunotherapy. Int J Pharm 542:253. CrossRefGoogle Scholar
  79. Türeli NG, Torge A, Juntke J, Schwarz BC, Schneider-Daum N, Türeli AE, Lehr C-M, Schneider M (2017) Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections. Eur J Pharm Biopharm 117:363–371. CrossRefGoogle Scholar
  80. Tzeng SY, Guarecuco R, McHugh KJ, Rose S, Rosenberg EM, Zeng Y, Langer R, Jaklenec A (2016) Thermostabilization of inactivated polio vaccine in PLGA-based microspheres for pulsatile release. J Control Release 233:101–113. CrossRefGoogle Scholar
  81. Vasir JK, Labhasetwar V (2007) Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev 59(8):718–728. CrossRefGoogle Scholar
  82. Wan F, Yang M (2016) Design of PLGA-based depot delivery systems for biopharmaceuticals prepared by spray drying. Int J Pharm 498(1):82–95. CrossRefGoogle Scholar
  83. Wang Q, Barry MA, Seid CA, Hudspeth EM, McAtee CP, Heffernan MJ (2017) 3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine. J Biomed Mater Res B Appl Biomater 106:1587. CrossRefGoogle Scholar
  84. Watkins HC, Pagan CL, Childs HR, Posada S, Chau A, Rios J, Guarino C, DeLisa MP, Whittaker GR, Putnam D (2017) A single dose and long lasting vaccine against pandemic influenza through the controlled release of a heterospecies tandem M2 sequence embedded within detoxified bacterial outer membrane vesicles. Vaccine 35:5373. CrossRefGoogle Scholar
  85. Yang HW, Ye L, Guo XD, Yang C, Compans RW, Prausnitz MR (2017) Ebola vaccination using a DNA vaccine coated on PLGA-PLL/γPGA nanoparticles administered using a microneedle patch. Adv Healthc Mater 6(1). CrossRefGoogle Scholar
  86. Zhang N-Z, Xu Y, Wang M, Chen J, Huang S-Y, Gao Q, Zhu X-Q (2016) Vaccination with Toxoplasma gondii calcium-dependent protein kinase 6 and rhoptry protein 18 encapsulated in poly (lactide-co-glycolide) microspheres induces long-term protective immunity in mice. BMC Infect Dis 16(1):168. CrossRefGoogle Scholar
  87. Zhao F, Zhao Y, Liu Y, Chang X, Chen C, Zhao Y (2011) Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small 7(10):1322–1337. CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Product Development Cell-IINational Institute of ImmunologyNew DelhiIndia

Personalised recommendations